drugset
Drugs / MART-1 peptide pulsed dendritic cells
last change May 2019 re-read 3 minutes ago

MART-1 peptide pulsed dendritic cells

Vaccine

Developed for
metastatic melanoma
Investigated by
California Institute of Technology · Jonsson Comprehensive Cancer Center · National Cancer Institute (NCI) · University of Connecticut · University of Southern California

Trials 1

today NCT00910650 · Ph 2
201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2 NCT00910650 Oct 2009 → May 2019 metastatic melanoma Jonsson Comprehensive Cancer Center Completed No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as MART-1 peptide pulsed dendritic cells ClinicalTrials.gov intervention name — accepted as the source's own label NCT00910650 ↗
Modality Vaccine “MART-1.26-35 peptide-pulsed dendritic cell (DC) vaccines” NCT00910650 ↗
Route Other “1 x 10(7) MART-1 peptide pulsed dendritic cells intradermally” NCT00910650 ↗